Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

Delayed Quote. Delayed  - 05/27 10:00:00 pm
85.82 USD   +0.62%
05/27 Levi & Korsinsky, LLP Announces the Commencement of an Investigat..
05/27 Pomerantz Law Firm Investigates Claims On Behalf of Investors of ..
05/27 GILEAD SCIENCES : European CHMP Adopts Positive Opinion for Gilead&r..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Gilead Sciences Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/27/2016 | 09:00pm CEST

Levi & Korsinsky announces it has commenced an investigation of Gilead Sciences Inc. (“Gilead Sciences” or the “Company”) (NASDAQ:GILD) concerning possible violations of federal securities laws.

On May 6, 2016, Gilead acknowledged receipt of a subpoena from the U.S. Attorney’s Office for the District of Massachusetts in February 2016. According to the Company, the subpoena requested documents related to the Company’s “support of 501(c)(3) organizations that provide financial assistance to patients, and for our HCV products, documents concerning our provision of financial assistance to patients.” Then on May 27, 2016, Bloomberg reported that Gilead is one of three major drugmakers to disclose in a recent SEC filing the receipt of a subpoena as part of this expanding federal investigation. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/gilead-sciences-gild

or contact Eduard Korsinsky, Esq. either via email at ek@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.


© Business Wire 2016
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on GILEAD SCIENCES, INC.
05/27 Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Pos..
05/27 Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Scien..
05/27 GILEAD SCIENCES : European CHMP Adopts Positive Opinion for Gilead’s Epclu..
05/25 GILEAD SCIENCES : Announces Appointment of Kevin Young CBE as Chief Operating Of..
05/25 GILEAD SCIENCES INC : Change in Directors or Principal Officers (form 8-K)
05/25 GILEAD SCIENCES : names Kevin Young as new Chief Operating Officer
05/24DJGILEAD SCIENCES : Names New Operating Chief
05/24 GILEAD SCIENCES : Announces Appointment of Kevin Young CBE as Chief Operating Of..
05/23 GILEAD SCIENCES : Breaking down barriers to HIV/Aids treatment – afternoon..
05/20 GILEAD SCIENCES : to Present at the UBS Global Healthcare Conference on Monday, ..
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials